ATE500265T1 - Synthetische mecp2-sequenz für die proteinersatztherapie - Google Patents

Synthetische mecp2-sequenz für die proteinersatztherapie

Info

Publication number
ATE500265T1
ATE500265T1 AT06724141T AT06724141T ATE500265T1 AT E500265 T1 ATE500265 T1 AT E500265T1 AT 06724141 T AT06724141 T AT 06724141T AT 06724141 T AT06724141 T AT 06724141T AT E500265 T1 ATE500265 T1 AT E500265T1
Authority
AT
Austria
Prior art keywords
protein
proteins
nucleic acid
relates
replacement therapy
Prior art date
Application number
AT06724141T
Other languages
English (en)
Inventor
Franco Laccone
Original Assignee
Univ Goettingen Georg August
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Goettingen Georg August filed Critical Univ Goettingen Georg August
Application granted granted Critical
Publication of ATE500265T1 publication Critical patent/ATE500265T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT06724141T 2006-04-07 2006-04-07 Synthetische mecp2-sequenz für die proteinersatztherapie ATE500265T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2006/003203 WO2007115578A1 (en) 2006-04-07 2006-04-07 Synthetic mecp2 sequence for protein substitution therapy

Publications (1)

Publication Number Publication Date
ATE500265T1 true ATE500265T1 (de) 2011-03-15

Family

ID=36589309

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06724141T ATE500265T1 (de) 2006-04-07 2006-04-07 Synthetische mecp2-sequenz für die proteinersatztherapie

Country Status (15)

Country Link
US (1) US8226930B2 (de)
EP (1) EP2010563B1 (de)
JP (1) JP5102283B2 (de)
CN (1) CN101415726B (de)
AT (1) ATE500265T1 (de)
AU (1) AU2006341726B2 (de)
CA (1) CA2647125C (de)
DE (1) DE602006020501D1 (de)
DK (1) DK2010563T3 (de)
ES (1) ES2362195T3 (de)
HR (1) HRP20110386T1 (de)
IL (1) IL194274A (de)
PL (1) PL2010563T3 (de)
SI (1) SI2010563T1 (de)
WO (1) WO2007115578A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1398191B1 (it) * 2010-02-17 2013-02-14 Ist Superiore Sanita Uso di tossine che attivano le rho gtpasi per il trattamento e/o la prevenzione della sintomatologia associata alla sindrome di rett (rtt).
AU2011325956B2 (en) 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
KR20150030205A (ko) 2012-05-16 2015-03-19 라나 테라퓨틱스, 인크. Smn 유전자 패밀리 발현을 조절하기 위한 조성물 및 방법
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
EA201492121A1 (ru) 2012-05-16 2015-10-30 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии семейства генов гемоглобина
JP2015523853A (ja) 2012-05-16 2015-08-20 ラナ セラピューティクス インコーポレイテッド Ａｔｐ２ａ２発現を調節するための組成物及び方法
AU2013262709A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
SG11201407486PA (en) 2012-05-16 2014-12-30 Rana Therapeutics Inc Compositions and methods for modulating utrn expression
WO2014130408A1 (en) * 2013-02-20 2014-08-28 The Research Foundation For The State University Of New York Regulators of rab5 activity
US10858650B2 (en) 2014-10-30 2020-12-08 The General Hospital Corporation Methods for modulating ATRX-dependent gene repression
WO2016149455A2 (en) 2015-03-17 2016-09-22 The General Hospital Corporation The rna interactome of polycomb repressive complex 1 (prc1)
TWI601821B (zh) * 2016-04-15 2017-10-11 中央研究院 治療神經發展性疾病
BR112018077225A2 (pt) * 2016-06-28 2019-04-09 Alma Mater Studiorum - Università di Bologna proteínas de fusão tatk-cdkl5, composições, formulações e uso das mesmas
ES3066629T3 (en) * 2017-03-24 2026-05-13 The Univ Court Of The Univ Of Edinburgh Mecp2 expression cassettes
US11629342B2 (en) 2017-10-17 2023-04-18 President And Fellows Of Harvard College Cas9-based transcription modulation systems
KR102052097B1 (ko) * 2017-11-30 2019-12-05 한국과학기술연구원 Mecp2 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물
KR20220003553A (ko) * 2019-04-24 2022-01-10 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 레트 증후군의 치료에 유용한 조성물
WO2023235648A1 (en) * 2022-06-03 2023-12-07 The Regents Of The University Of California Nuclear Delivery and Transcriptional Repression with a Cell-penetrant MeCP2
CN119971036A (zh) * 2023-11-13 2025-05-13 中国科学院分子细胞科学卓越创新中心 核糖核酸酶RNase H修复神经元树突生长缺陷的应用和方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2364690A1 (en) * 1999-02-28 2000-10-19 Washington University Novel transduction molecules and methods for using same
US6709817B1 (en) 1999-09-07 2004-03-23 Baylor College Of Medicine Method of screening Rett syndrome by detecting a mutation in MECP2
US20040126877A1 (en) * 2001-04-20 2004-07-01 Man-Wook Hur Repressors for hiv transcription and methods thereof
JP5830213B2 (ja) * 2004-02-17 2015-12-09 ザ ホスピタル フォー シック チルドレン Ｍｅｃｐ２ｅ１遺伝子

Also Published As

Publication number Publication date
SI2010563T1 (sl) 2011-07-29
US20090233856A1 (en) 2009-09-17
AU2006341726A1 (en) 2007-10-18
EP2010563A1 (de) 2009-01-07
IL194274A (en) 2011-07-31
JP5102283B2 (ja) 2012-12-19
PL2010563T3 (pl) 2011-11-30
CA2647125A1 (en) 2007-10-18
CN101415726A (zh) 2009-04-22
DK2010563T3 (da) 2011-05-23
ES2362195T3 (es) 2011-06-29
DE602006020501D1 (de) 2011-04-14
US8226930B2 (en) 2012-07-24
HRP20110386T1 (hr) 2011-08-31
CA2647125C (en) 2015-02-03
JP2009532045A (ja) 2009-09-10
EP2010563B1 (de) 2011-03-02
CN101415726B (zh) 2013-07-31
HK1121468A1 (en) 2009-04-24
AU2006341726B2 (en) 2012-09-20
WO2007115578A8 (en) 2008-10-30
WO2007115578A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
DE602006020501D1 (de) Synthetische mecp2-sequenz für die proteinersatztherapie
MX2009012650A (es) Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
PH12012502272A1 (en) Biological materials related to her3
BR112019005587A2 (pt) proteínas de ligação recombinantes e sua utilização
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
IN2012DN02981A (de)
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
BR112016002753A2 (pt) anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
EP4435007A3 (de) Trispezifische proteine und verfahren zur verwendung
BRPI1010880A2 (pt) polipeptídeos de hormônio de crescimento e métodos de fazer e usar os mesmos.
BR112013029409A2 (pt) "produto de peptídeo compreendendo tensoativo ligado de forma covalente a peptídeo, composição farmacêutica que o compreende, bem como uso de produto de peptídeo no tratamento de condição associada à resistência à insulina, doença cardiovascular e diabetes"
CA2818990A1 (en) Designed repeat proteins binding to serum albumin
WO2011036442A3 (en) Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders
MY162564A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
MX2019002345A (es) Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
CU23932B1 (es) Sales farmacéuticamente aceptables de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo y sus usos en terapia
PH12013500910A1 (en) Cxcr2 binding polypeptides
EP2557090A3 (de) Gegen GPCRs gerichtete Aminosäuresequenzen und Polypeptide damit zur Behandlung von Krankheiten und Störungen im Zusammenhang mit GPCR
NO20054769D0 (no) Substituerte fenylalkansyrer
WO2008052173A8 (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
ATE489371T1 (de) Benzamidglucokinaseaktivatoren
BR112014024282A2 (pt) anticorpos ligantes ao receptor b1 da bradicinina
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
WO2020198662A8 (en) Clec9a-based chimeric protein complexes
WO2010011994A3 (en) Polypeptides and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2010563

Country of ref document: EP